FDA Reverses Decision on Rare Blood Cancer Drug, Cigna Expands with CarepathRx Acquisition
FDA reverses its initial approval of a rare blood cancer drug, raising concerns about regulatory stability. Separately, Cigna acquires CarepathRx to deepen its presence in hospital pharmacy services, marking a significant expansion.
· 98d ago
